Join the Oncology Voice Network. Join for Free
Layoff Ready... How to Plan and Prepare for Potential Career Transition
career transition strategies career progression important skills for MSLs pivot from layoff personal growth and development

Layoff Ready... How to Plan and Prepare for Potential Career Transition


Share This Article


Summary

Chad Schroer, Senior Director, USMA Field Medical Excellence at BeiGene, we discuss strategies to prepare yourself for career transition – whether it’s to grow in your current role, move into a new role or to find a new role due to a layoff.

Learn more about…

👉 Career progression strategies and how to position yourself
👉 Skills that are most important for MSLs in their career planning
👉 How to pivot from a layoff and set yourself up for your next role
👉 What MSLs should be doing for personal growth and development
👉 What companies and MSL Managers can do better

Click for Source
career transition strategies, career progression, important skills for MSLs, pivot from layoff, personal growth and development

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Promotability: How to Land Your Next Promotion
Partner Avatar Tom Caravela

Promotability: How to Land Your Next Promotion

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Podcast
Why Chasing Titles is Fools Gold
Partner Avatar MSL Talk: Tom Caravela, Archie Stone

Why Chasing Titles is Fools Gold

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Explore OVN